Highlights Surrozen, Inc.

Equities

SRZN

US86889P2083

Market Closed - Nasdaq Other stock markets 21:30:00 08/05/2024 BST			5-day change	1st Jan Change
10.2 ^USD	+2.41%		+3.13%	+8.51%

04-10	Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-08	Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-10	CI
Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis	04-01	CI
Surrozen, Inc. Provides Corporate Update on Clinical Programs	01-18	CI
Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis	11-08	CI
Surrozen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
Surrozen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	22/03/23	CI
Tranche Update on Surrozen, Inc.'s Equity Buyback Plan announced on December 15, 2022.	15/12/22	CI
Surrozen, Inc. announces an Equity Buyback for 1,310,496 shares, for $2.7 million.	15/12/22	CI
Surrozen, Inc.'s Equity Buyback announced on December 15, 2022, has closed with 1,310,496 shares, for $2.7 million.	14/12/22	CI
Surrozen, Inc. authorizes a Buyback Plan.	11/12/22	CI
Surrozen, Inc. Updates SZN-1326, SZN-043 and SZN-413 for Vascular-Associated Retinopathies, Including Diabetic Retinopathy and Diabetic Macular Edema	16/11/22	CI
Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Surrozen, Boehringer Ingelheim to Support Research, Development of Retinal Diseases Treatment	06/10/22	MT
Surrozen, Inc. Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases	06/10/22	CI
Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of Szn-413 in Preclinical Models of Diabetic Retinopathy	26/09/22	CI
Surrozen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/08/22	CI
Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis	13/06/22	CI
Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week	24/05/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Surrozen, Inc.

Equities

SRZN

US86889P2083

Highlights

Filters